Interview: Novartis Takes Virtual Route To Transform Clinical Trial Paradigm
Jake LaPorte, head of digital development at the Swiss major, has told Scrip that the expansion of Novartis' collaboration with Science 37 will move decentralized trials away from the pilot stage into a scaleable model that will have a genuine impact on the way R&D is conducted in the future.
You may also be interested in...
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.
One day in the future, clinical studies may routinely be carried out in the virtual world, with patients mostly staying put at home instead of traveling to trial sites. For now, sponsors are experimenting with new models for drug development and taking it one step at a time.
Celgene will pursue "high-impact" indications using Vividion's proteomics technology, while Magenta will use Heidelberg's technology to try to optimize bone marrow transplants.